Literature DB >> 25646042

Serum Testosterone, 17β-Estradiol and PSA Levels in Subjects with Prostate Disorders.

Anthony J Usoro1, Aniebietabasi S Obot2, Itemobong S Ekaidem1, Okon E Akaiso3, Alphonsus E Udoh4, O Akinloye5.   

Abstract

Prostate carcinoma is the most frequently diagnosed malignancy and the second leading cause of death as a result of cancer in men in the US and other parts of the world. There are conflicting reports on the serum levels of testosterone and 17β-estradiol (E2) in benign prostatic hyperplasia (BPH) and prostate cancer. This study was designed to evaluate the serum concentrations of these hormones in patients with these disorders. Serum levels of prostate specific antigen (PSA), total testosterone and estradiol were determined in 228 subjects comprising of 116 subjects with BPH, 62 subjects with prostate cancer (CaP) and 50 age-matched apparently healthy controls, using ELISA methods. PSA levels were significantly elevated (p < 0.05) in BPH subjects than controls, while there was no significant difference (p > 0.05) in testosterone and estradiol levels of these subjects. PSA and estradiol levels were significantly higher (p < 0.05) in CaP subjects than in controls, while there was no observed significant difference (p > 0.05) in testosterone levels. CaP subjects had significantly raised PSA, testosterone, and estradiol levels than BPH subjects. The mean molar ratio of testosterone: E2 was lowest among CaP patients (134:1) and highest among controls (166:1). Significant positive correlation between PSA and 17β-estradiol was observed in prostate disorders (BPH and CaP patients: r = 0.347; p = 0.000). Significant negative correlations between testosterone and PSA were also observed among BPH patients (r = -0.221, p = 0.049) and control subjects (r = -0.490, p = 0.000). No significant correlation existed between testosterone and PSA in CaP patients (r = 0.051, p = 0.693). Correlations between age and estradiol in both BPH and CaP were not significant (p > 0.05). This study has shown that, there was a significant increase in serum estradiol in CaP subjects, while the testosterone levels in both BPH and CaP subjects were not different from those of controls.

Entities:  

Keywords:  BPH; Estradiol; Molar ratio; PSA; Prostate cancer; Testosterone

Year:  2014        PMID: 25646042      PMCID: PMC4310840          DOI: 10.1007/s12291-013-0411-3

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  29 in total

1.  Signaling through estrogen receptors modulates telomerase activity in human prostate cancer.

Authors:  Simona Nanni; Michela Narducci; Linda Della Pietra; Fabiola Moretti; Annalisa Grasselli; Piero De Carli; Ada Sacchi; Alfredo Pontecorvi; Antonella Farsetti
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  Cloning of a novel receptor expressed in rat prostate and ovary.

Authors:  G G Kuiper; E Enmark; M Pelto-Huikko; S Nilsson; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  Migration and prostate cancer: an international perspective.

Authors:  F F Angwafo
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

4.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Authors:  S M Harman; E J Metter; J D Tobin; J Pearson; M R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

Review 5.  Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models.

Authors:  M C Bosland
Journal:  Prog Clin Biol Res       Date:  1996

6.  Primary carcinoma of the prostate in Ibadan.

Authors:  E O Nkposong; J Lawani
Journal:  West Afr Med J Niger Med Dent Pract       Date:  1973-12

7.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

Review 8.  Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts.

Authors:  P Ekman
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

Review 9.  Hormones and prostate cancer: current perspectives and future directions.

Authors:  Ann W Hsing; Juergen K V Reichardt; Frank Z Stanczyk
Journal:  Prostate       Date:  2002-08-01       Impact factor: 4.104

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  4 in total

1.  Endogenous testosterone as a predictor of prostate growing disorders in the aging male.

Authors:  Antonio Benito Porcaro; Nelia Amigoni; Alessandro Tafuri; Riccardo Rizzetto; Aliasger Shakir; Leone Tiso; Clara Cerrato; Vincenzo Lacola; Stefano Zecchini Antoniolli; Alessandra Gozzo; Katia Odorizzi; Matteo Brunelli; Filippo Migliorini; Walter Artibani; Maria Angela Cerruto; Salvatore Siracusano; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2021-01-03       Impact factor: 2.370

2.  Androgenic modulation of AR-Vs.

Authors:  Ana Caroline Hillebrand; Lolita Schneider Pizzolato; Gisele Branchini; Ilma Simoni Brum
Journal:  Endocrine       Date:  2018-07-19       Impact factor: 3.633

3.  Finasteride accelerates prostate wound healing after thulium laser resection through DHT and AR signalling.

Authors:  Ruizhe Zhao; Xingjie Wang; Chenyi Jiang; Fei Shi; Yiping Zhu; Boyu Yang; Jian Zhuo; Yifeng Jing; Guangheng Luo; Shujie Xia; Bangmin Han
Journal:  Cell Prolif       Date:  2017-11-30       Impact factor: 6.831

4.  Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result.

Authors:  Alexandros Fiamegos; John Varkarakis; Michael Kontraros; Andreas Karagiannis; Michael Chrisofos; Dimitrios Barbalias; Charalampos Deliveliotis
Journal:  Int Braz J Urol       Date:  2016 Sep-Oct       Impact factor: 1.541

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.